risks of glp-1 drugs America's Poison Centers GLP-1 Medications for Weight Loss:

MEDI0832 (now known as cotadutide) is a balanced co-agonist based on the peptide sequence of glucagon, modified at specific amino acid positions in addition to a palmitic fatty acid side chain to prolong activity

Such differences in compliance between GLP-1RA preparations are mainly due to the differences between injection devices [172]

BMJ Qual Saf 23(11):957964

Always review the product-specific requirements in the application

Osteometabolism: Metabolic alterations in bone pathologies

SGLT2 inhibitors are preferred in people with HF or at high-risk for HF, whereas GLP-1 receptor agonists are favored for those requiring significant weight loss, ASCVD risk reduction, CKD management, or in whom mitigation of metabolic dysfunction-associated steatotic liver disease (MASLD) or steatohepatitis is a clinical priority [84]